Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Up 108.8% in January

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 358,088 shares, an increase of 108.8% from the December 31st total of 171,538 shares. Based on an average daily volume of 156,481 shares, the days-to-cover ratio is presently 2.3 days. Approximately 17.9% of the shares of the company are short sold. Approximately 17.9% of the shares of the company are short sold. Based on an average daily volume of 156,481 shares, the days-to-cover ratio is presently 2.3 days.

Moleculin Biotech Stock Down 0.9%

Shares of NASDAQ:MBRX traded down $0.04 during trading on Friday, hitting $4.24. 17,512 shares of the stock traded hands, compared to its average volume of 137,292. The company has a fifty day moving average price of $5.07 and a two-hundred day moving average price of $10.28. Moleculin Biotech has a 52-week low of $3.13 and a 52-week high of $91.25. The company has a market cap of $8.63 million, a price-to-earnings ratio of -0.13 and a beta of 1.62.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.07. On average, equities research analysts predict that Moleculin Biotech will post -7.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Moleculin Biotech to a “strong sell” rating in a report on Friday, October 3rd. Roth Mkm reiterated a “buy” rating on shares of Moleculin Biotech in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $22.00 target price (up from $4.00) on shares of Moleculin Biotech in a research report on Thursday, December 11th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Moleculin Biotech currently has an average rating of “Moderate Buy” and an average price target of $61.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.